Vyome to Present VT-1953 Study Data at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy HIND?
Vyome Holdings will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds at the 2026 American Association for Cancer Research Annual Meeting, taking place on April 17-22, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved drugs to treat malodor and other symptoms of MFW. We plan to have FDA interactions in Q2 2026 on the pivotal study design. Recent third-party analysts estimated the total addressable U.S. market to be approximately $2.2B. Inflammation is one of the biggest healthcare problems facing the world today." The research will be presented at the session "Phase II and Phase III Clinical Trials in Progress." Vyome will highlight mechanistic insights together with detailed clinical data comparing the VT-1953 active treatment with vehicle treatment in a Phase 2 study. VT-1953 is a first-in-class treatment for malodor and other symptoms of MFW in advanced cancer patients, which acts by a dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. MFW is a rare, debilitating condition that occurs in ~10% of advanced cancer patients, severely impacting the quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIND
Wall Street analysts forecast HIND stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.350
Low
15.00
Averages
15.00
High
15.00
Current: 2.350
Low
15.00
Averages
15.00
High
15.00
No data
About HIND
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vyome Holdings Reports FY 2025 Financial Results
- Financial Overview: Vyome Holdings reported FY 2025 revenue of $0.32 million, indicating challenges in market performance, and despite having approximately $4.94 million in cash and short-term investments, the company needs to enhance revenue for sustainable growth.
- Cash Position: As of December 31, 2025, the company holds approximately $4.94 million in cash and equivalents, with an additional $5.3 million expected from an ATM agreement in January 2026, ensuring operational funding for the near future.
- Loss Report: The net loss of $10,477,713 primarily reflects one-time merger and financing-related expenses of about $7.7 million, which puts pressure on the company's financial health, necessitating close attention to future cost control measures.
- Research Outlook: The anticipated interim analysis of the pivotal VT-1953 study around mid-2027 presents a potential growth opportunity, although the current financial situation is challenging, successful clinical trials could lead to new avenues for revenue generation.
See More
Vyome Publishes Preclinical Data for VT-1908
- Preclinical Data Release: Vyome Holdings, Inc. published preclinical data in the Journal of Ophthalmic Inflammation and Infection, validating the efficacy and safety of VT-1908 for treating uveitis, highlighting its potential as a steroid alternative to meet the urgent market demand for safe therapies.
- Significant Market Opportunity: Uveitis accounts for 10-15% of blindness cases in developed countries, with an estimated market opportunity of $3 billion by 2032, positioning VT-1908 for a substantial market share if successfully developed.
- Clinical Development Plans: Vyome intends to leverage the India innovation corridor to advance VT-1908 into clinical development in a highly cost-efficient manner, aiming to generate critical human clinical data that could lead to significant value inflection for the company.
- Focus on Core Programs: While advancing the Phase 3 study of VT-1953, Vyome maintains its capital deployment plan unchanged, ensuring resources are concentrated on the treatment of malignant fungating wounds, which represents a $2.2 billion market opportunity in the U.S.
See More
Harvest Announces 2025 ETF Reinvested Distributions
- Annual Reinvested Distributions: Harvest Portfolios Group has announced the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged, thereby maintaining asset stability for investors.
- Tax Implications Explained: The distributions will be reported as taxable, which will increase each unitholder's adjusted cost base, impacting future tax handling and ensuring investors are aware of their tax responsibilities.
- Distribution Details Update: All final reinvested capital gain and income distributions for Harvest ETFs are reported as zero, reflecting the company's cautious strategy in the current market environment aimed at protecting investor interests.
- Enhanced Information Transparency: Harvest commits to reporting the actual taxable amounts and nature of distributions to brokers through CDS in early 2026, enhancing transparency and aiding investors in making informed decisions.
See More
Harvest Announces Final Annual Reinvested Distributions for 2025 Tax Year
- Reinvestment Distribution Announcement: Harvest Portfolios Group Inc. announces the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged.
- Tax Implications Explained: The distributions will be reported as taxable, expected to be communicated to brokers through CDS in early 2026, which will increase each unitholder's adjusted cost base and impact future tax considerations.
- Distribution Details Update: All Harvest ETFs report zero reinvested capital gain and income distributions, indicating no distributable earnings for the year, which may affect investor return expectations.
- Record Date Set: December 31, 2025, is established as the ex-dividend date for all unitholders of record, ensuring investors are informed of distribution details to make timely investment decisions.
See More
Harvest ETFs Updates 2025 Estimated Reinvested Distributions
- Distribution Amount Revision: Harvest has announced a revision of the estimated reinvested distributions for 2025, which will be reported to brokers through CDS in early 2026, ensuring investors are informed about tax implications.
- Non-Cash Distribution Mechanism: The annual distributions for all Harvest ETFs will be reinvested in a non-cash format, ensuring that the number of units held and the net asset value remain unchanged, thereby maintaining asset stability for investors.
- Tax Implications Explained: The reinvested distributions will be treated as taxable distributions, increasing each unitholder's adjusted cost base, which will impact future tax planning.
- Final Distribution Announcement: Harvest expects to announce the final year-end reinvested distribution amounts around December 31, 2025, ensuring investors receive timely access to critical information.
See More
Vyome's VT-1953 Treatment Significantly Improves Malodor in Malignant Wounds
- Clinical Trial Success: Vyome's VT-1953 treatment achieved statistically significant improvements in malodor associated with malignant wounds within 14 days (P=0.002), laying the groundwork for entering a $1 billion market opportunity.
- Quality of Life Enhancement: The significant improvement in the patient-reported impact of malodor on quality of life (P=0.0256) not only boosts patient mental health but also potentially enhances Vyome's competitive position in the market.
- Pain Relief Effectiveness: VT-1953 demonstrated significant pain reduction (P=0.002), indicating its potential in improving overall patient health outcomes and satisfaction.
- Future Development Plans: Vyome aims to initiate a Phase III clinical trial in 2026 to further advance VT-1953 towards FDA approval, reflecting the company's confidence in the product and its market prospects.
See More
Vyome Holdings Reports FY 2025 Financial Results
- Financial Overview: Vyome Holdings reported FY 2025 revenue of $0.32 million, indicating challenges in market performance, and despite having approximately $4.94 million in cash and short-term investments, the company needs to enhance revenue for sustainable growth.
- Cash Position: As of December 31, 2025, the company holds approximately $4.94 million in cash and equivalents, with an additional $5.3 million expected from an ATM agreement in January 2026, ensuring operational funding for the near future.
- Loss Report: The net loss of $10,477,713 primarily reflects one-time merger and financing-related expenses of about $7.7 million, which puts pressure on the company's financial health, necessitating close attention to future cost control measures.
- Research Outlook: The anticipated interim analysis of the pivotal VT-1953 study around mid-2027 presents a potential growth opportunity, although the current financial situation is challenging, successful clinical trials could lead to new avenues for revenue generation.
See More
Vyome Publishes Preclinical Data for VT-1908
- Preclinical Data Release: Vyome Holdings, Inc. published preclinical data in the Journal of Ophthalmic Inflammation and Infection, validating the efficacy and safety of VT-1908 for treating uveitis, highlighting its potential as a steroid alternative to meet the urgent market demand for safe therapies.
- Significant Market Opportunity: Uveitis accounts for 10-15% of blindness cases in developed countries, with an estimated market opportunity of $3 billion by 2032, positioning VT-1908 for a substantial market share if successfully developed.
- Clinical Development Plans: Vyome intends to leverage the India innovation corridor to advance VT-1908 into clinical development in a highly cost-efficient manner, aiming to generate critical human clinical data that could lead to significant value inflection for the company.
- Focus on Core Programs: While advancing the Phase 3 study of VT-1953, Vyome maintains its capital deployment plan unchanged, ensuring resources are concentrated on the treatment of malignant fungating wounds, which represents a $2.2 billion market opportunity in the U.S.
See More
Harvest Announces 2025 ETF Reinvested Distributions
- Annual Reinvested Distributions: Harvest Portfolios Group has announced the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged, thereby maintaining asset stability for investors.
- Tax Implications Explained: The distributions will be reported as taxable, which will increase each unitholder's adjusted cost base, impacting future tax handling and ensuring investors are aware of their tax responsibilities.
- Distribution Details Update: All final reinvested capital gain and income distributions for Harvest ETFs are reported as zero, reflecting the company's cautious strategy in the current market environment aimed at protecting investor interests.
- Enhanced Information Transparency: Harvest commits to reporting the actual taxable amounts and nature of distributions to brokers through CDS in early 2026, enhancing transparency and aiding investors in making informed decisions.
See More
Harvest Announces Final Annual Reinvested Distributions for 2025 Tax Year
- Reinvestment Distribution Announcement: Harvest Portfolios Group Inc. announces the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged.
- Tax Implications Explained: The distributions will be reported as taxable, expected to be communicated to brokers through CDS in early 2026, which will increase each unitholder's adjusted cost base and impact future tax considerations.
- Distribution Details Update: All Harvest ETFs report zero reinvested capital gain and income distributions, indicating no distributable earnings for the year, which may affect investor return expectations.
- Record Date Set: December 31, 2025, is established as the ex-dividend date for all unitholders of record, ensuring investors are informed of distribution details to make timely investment decisions.
See More
Harvest ETFs Updates 2025 Estimated Reinvested Distributions
- Distribution Amount Revision: Harvest has announced a revision of the estimated reinvested distributions for 2025, which will be reported to brokers through CDS in early 2026, ensuring investors are informed about tax implications.
- Non-Cash Distribution Mechanism: The annual distributions for all Harvest ETFs will be reinvested in a non-cash format, ensuring that the number of units held and the net asset value remain unchanged, thereby maintaining asset stability for investors.
- Tax Implications Explained: The reinvested distributions will be treated as taxable distributions, increasing each unitholder's adjusted cost base, which will impact future tax planning.
- Final Distribution Announcement: Harvest expects to announce the final year-end reinvested distribution amounts around December 31, 2025, ensuring investors receive timely access to critical information.
See More
Vyome's VT-1953 Treatment Significantly Improves Malodor in Malignant Wounds
- Clinical Trial Success: Vyome's VT-1953 treatment achieved statistically significant improvements in malodor associated with malignant wounds within 14 days (P=0.002), laying the groundwork for entering a $1 billion market opportunity.
- Quality of Life Enhancement: The significant improvement in the patient-reported impact of malodor on quality of life (P=0.0256) not only boosts patient mental health but also potentially enhances Vyome's competitive position in the market.
- Pain Relief Effectiveness: VT-1953 demonstrated significant pain reduction (P=0.002), indicating its potential in improving overall patient health outcomes and satisfaction.
- Future Development Plans: Vyome aims to initiate a Phase III clinical trial in 2026 to further advance VT-1953 towards FDA approval, reflecting the company's confidence in the product and its market prospects.
See More
